Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

키워드

참고문헌 (7)

1. Iwaki M, "Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease : A sub-analysis of the CLIONE study", Clin Mol Hepatol, 30, pp.225~234 (2024)
2. Le MH, "Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach", Clin Mol Hepatol, 28, pp.841~850 (2022)
3. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
4. Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
5. Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
6. Konyn P, "Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease", Clin Mol Hepatol, 29(Suppl), pp.S43~S57 (2023)
7. Song SJ, "Can we use old NAFLD data under the new MASLD definition?", J Hepatol, 80, pp.e54~e56 (2024)

관련 논문AI추천